These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18337559)

  • 1. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
    Xiong W; Wu X; Starnes S; Johnson SK; Haessler J; Wang S; Chen L; Barlogie B; Shaughnessy JD; Zhan F
    Blood; 2008 Nov; 112(10):4235-46. PubMed ID: 18337559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
    Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
    Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis, Biology, and Targeting of
    Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
    Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hierarchy of mono- and biallelic
    Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
    Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
    [No Abstract]   [Full Text] [Related]  

  • 7. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
    Gillardin PS; Descamps G; Maiga S; Tessoulin B; Djamai H; Lucani B; Chiron D; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C; Moreau-Aubry A
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
    Feng X; Guo J; An G; Wu Y; Liu Z; Meng B; He N; Zhao X; Chen S; Zhu Y; Xia J; Li X; Yu Z; Li R; Ren G; Chen J; Wu M; He Y; Qiu L; Zhou J; Zhou W
    Adv Sci (Weinh); 2022 Mar; 9(9):e2104491. PubMed ID: 35088582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma.
    Tang X; Chen Y
    Hematology; 2024 Dec; 29(1):2377850. PubMed ID: 39012217
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Drozdkova DH; Gursky J; Minarik J; Überall I; Kolar Z; Trtkova KS
    Anticancer Res; 2020 Sep; 40(9):4979-4987. PubMed ID: 32878786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
    Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
    Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclonal
    Shah V; Johnson DC; Sherborne AL; Ellis S; Aldridge FM; Howard-Reeves J; Begum F; Price A; Kendall J; Chiecchio L; Savola S; Jenner MW; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Davies FE; Houlston RS; Cook G; Cairns DA; Jackson G; Kaiser MF;
    Blood; 2018 Dec; 132(23):2465-2469. PubMed ID: 30373884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
    Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
    Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
    Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
    Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
    J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
    Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.